Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the following Formula I:



I

wherein:

R_1 has the formula alkylene-L-R_{1-1}, alkenylene-L-R_{1-1}, or alkynylene-L-R_{1-1}, wherein:

the alkylene, alkenylene, and alkynylene groups are optionally interrupted with one or more -O- groups;

L is a bond or a functional linking group selected from the group consisting of -NH-$S(O)_2$-, -NH-C(O)-, -NH-C(S)-, -NH-$S(O)_2$-NR_3-, -NH-C(O)-NR_3-, -NH-C(S)-NR_3-, -NH-C(O)-O-, -O-, -S-, and -$S(O)_2$-; and

R_{1-1} is a linear or branched aliphatic group having at least 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

R" is selected from the group consisting of:

hydrogen;

alkyl;

alkenyl;

aryl;

heteroaryl;

heterocyclyl;

alkylene-Y-alkyl;

alkylene-Y-alkenyl;

alkylene-Y-aryl; and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

halogen;

$-N(R_4)_2$;

$-C(O)-C_{1-10}$alkyl;

$-C(O)-O-C_{1-10}$alkyl;

$-N_3$;

aryl;

heteroaryl;

heterocyclyl;

-C(O)-aryl; and

-C(O)-heteroaryl;

wherein: Y is –O– or $-S(O)_{0-2}-$; and each R_4 is independently selected from the group consisting of hydrogen, C_{1-10}alkyl, and C_{2-10}alkenyl~~hydrogen or a non-interfering substituent~~;

R_A and R_B are each independently selected from the group consisting of:

hydrogen,

halogen,

alkyl,

alkenyl,

alkoxy,

alkylthio, and

$-N(R_3)_2$;

or when taken together, R_A and R_B form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups;

or when taken together, R_A and R_B form a fused 5- to 7-membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;

each R is independently selected from the group consisting of

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

$-N(R_3)_2$; ~~R_A and R_B form a fused aryl ring or heteroaryl ring containing one heteroatom or a fused 5- to 7-membered saturated ring, optionally containing one heteroatom, wherein the heteroatom is selected from the group consisting of N and S, and wherein the aryl, heteroaryl, or 5- to 7-membered saturated ring is unsubstituted or substituted by one or more non-interfering substituents;~~ and

each R_3 is independently selected from the group consisting of hydrogen and alkyl;

with the proviso that when L is $-NH-S(O)_2-$ and R_A and R_B join to form an unsubstituted benzene ring, R_{1-1} is a linear or branched aliphatic group having greater than 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds; and with the further proviso that when L is -NH-C(O)- and R_A and R_B join to form an unsubstituted pyridine ring, R_{1-1} is a linear or branched aliphatic group having greater than 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

or a pharmaceutically acceptable salt thereof.

2-6 (canceled)

7. (currently amended) The compound or salt of claim 16 wherein R_A and R_B form a fused benzene ring which is unsubstituted.

8-10 (canceled)

11. (currently amended) The compound or salt of claim 10 wherein L is a bond or a functional linking group selected from the group consisting of -NH-C(O)-, $-NH-S(O)_2-$, and $-NH-C(O)-N(R_3)-$.

12 (canceled)

13. (currently amended) The compound or salt of claim 12 wherein R_{1-1} is a linear or branched aliphatic group having 12-20 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds.

14. (original) The compound or salt of claim 13 wherein R_{1-1} is a straight chain C_{12}-C_{20}alkyl.

15-16 (canceled)

17. (currently amended) The compound or salt of claim 16 wherein R_1 has the formula C_{1-5}alkylene-L-R_{1-1} and the C_{1-5}alkylene is optionally interrupted with one -O- group.

18. (currently amended) The compound or salt of claim 15 wherein R_2 is selected from the group consisting of hydrogen, alkyl, and alkylene-O-alkyl.

19 (canceled)

20. (original) A compound of the following Formula III:



III

wherein:

R_1 has the formula alkylene-L-R_{1-1}, alkenylene-L-R_{1-1}, or alkynylene-L-R_{1-1}, wherein:

the alkylene, alkenylene, and alkynylene groups are optionally interrupted with one or more -O- groups;

L is a bond or a functional linking group selected from the group consisting of -NH-S(O)$_2$-, -NH-C(O)-, -NH-C(S)-, -NH-S(O)$_2$-NR$_3$-, -NH-C(O)-NR$_3$-, -NH-C(S)-NR$_3$-, -NH-C(O)-O-, -O-, -S-, and -S(O)$_2$-; and

R_{1-1} is a linear or branched aliphatic group having at least 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

R is selected from the group consisting of

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

-N(R_3)$_2$;

n is 0 to 4;

R_2 is selected from the group consisting of:

hydrogen;

alkyl;

alkenyl;

aryl;

heteroaryl;

heterocyclyl;

alkylene-Y-alkyl;

alkylene-Y- alkenyl;

alkylene-Y-aryl; and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

halogen;

-N(R_4)$_2$;

-C(O)-C_{1-10}alkyl;

-C(O)-O-C_{1-10}alkyl;

$-N_3$;

aryl;

heteroaryl;

heterocyclyl;

-C(O)-aryl; and

-C(O)-heteroaryl;

Y is –O– or $-S(O)_{0-2}$-;

each R_4 is independently selected from the group consisting of hydrogen, C_{1-10}alkyl, and C_{2-10}alkenyl; and

R_3 is selected from the group consisting of hydrogen and alkyl;

with the proviso that when L is -NH-$S(O_2)$-, and n is 0, R_{1-F} is a linear or branched aliphatic group having at least 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

or a pharmaceutically acceptable salt thereof.

21. (original) The compound or salt of claim 20 wherein n is 0.

22-23 (canceled)

24. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of ~~any one of~~ claims 1 ~~through 23~~ in combination with a pharmaceutically acceptable carrier.

25. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of ~~any one of~~ claims 1 ~~through 23~~ to the animal.

26-27 (canceled)

28. (currently amended) A method of vaccinating an animal comprising administering an effective amount of a compound or salt of ~~any one of~~ claims 1 ~~through 23~~ to the animal as a vaccine adjuvant.

29. (currently amended) A method of vaccinating an animal comprising administering an effective amount of *N*-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)hexadecanamide to the animal as a vaccine adjuvant.

30-32 (canceled)

33. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 20 in combination with a pharmaceutically acceptable carrier.

34. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 20 to the animal.

35. (new) A method of vaccinating an animal comprising administering an effective amount of a compound or salt of claim 20 to the animal as a vaccine adjuvant.